Results 331 to 340 of about 1,888,881 (401)

Signaling pathways in systemic lupus erythematosus and therapeutic implications. [PDF]

Front Immunol
Balogh L, Kovács VG, Nagy G, Németh T.
europepmc   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Age- and Sex-Dependent Variation in the Type I Interferon Signature of Healthy Individuals. [PDF]

Medicina (Kaunas)
Galliano I, Volpe M, Calvi C, Pavan M, Massobrio A, Gambarino S, Albiani R, Linari C, Clemente A, Pau A, Montanari P, Bergallo M.   +11 more
europepmc   +1 more source

Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy

Advanced Science, EarlyView.
This study introduces MnSTF, a soft‐drug‐inspired nanoadjuvant that overcomes the systemic toxicity of STING agonists. Through Mn2+ coordination with an ENPP1 inhibitor, it enables safe cGAS‐STING activation, remodels the tumor immune microenvironment, and synergizes with radiotherapy or vaccines to elicit robust antitumor immunity.
Guangfei Sun, Jiancheng Pan, Rui Li, Ruoxi Li, Ziyan Liu, Jinhui Wu, Tingsheng Lin, Yiqiao Hu, Ahu Yuan   +8 more
wiley   +1 more source

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review. [PDF]

Int J Mol Sci
Tjiu JW, Tsai TF.
europepmc   +1 more source

Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity

Advanced Science, EarlyView.
Attaching antibodies against endothelial cell surface proteins redirects the delivery and expression of DNA‐lipid nanoparticles to organs of interest. Our targeted nanoparticles enable organ‐selective DNA expression in the endothelium of the lungs, brain, or spleen, providing a therapeutic platform for dozens of endothelial‐centric diseases.
Nicolas Marzolini, Taylor V. Brysgel, Ryan J. Rahman, Eno‐Obong Essien, Saw Y. Nwe, Jichuan Wu, Aparajeeta Majumder, Manthan N. Patel, Sachchidanand Tiwari, Carolann L. Espy, Fengyi Dong, Sabrina A. Santos‐De León, Anit Shah, Vladimir V. Shuvaev, Elizabeth D. Hood, Liam S. Chase, Drew Weissman, Jeremy B. Katzen, David B. Frank, Mariko L. Bennett, Oscar A. Marcos‐Contreras, Jacob W. Myerson, Vladimir R. Muzykantov, Sahily Reyes‐Esteves, Jacob S. Brenner   +24 more
wiley   +1 more source

Host Cell Virus Interactions: Molecular Mechanisms, Immune Modulation, Viral Pathogenesis, and Emerging Therapeutic Targets. [PDF]

Viruses
Alanazi A, Ibrahim MN, El Azab EF, Elithy MA.   +3 more
europepmc   +1 more source

EGR Proteins Mediate Interferon‐Independent Anti‐HSV‐1 Responses Through Viral and Host Targets

Advanced Science, EarlyView.
Early antiviral responses are typically mediated by interferons. However, during HSV‐1 infection, host early growth response (Egr) genes, which are not interferon‐stimulated genes, are quickly induced by viral protein ICP0. EGR proteins, in turn, suppress viral lytic infection by activating viral latency‐associated (LAT) and host immune regulatory ...
Shuaishuai Wang, Fujun Hou, Xunuo Jin, Yuhang Xiang, Dongli Pan   +4 more
wiley   +1 more source

Claudin-4 as a dual regulator of genome stability and immune evasion in high grade serous ovarian cancer. [PDF]

Sci Rep
Bitler BG, Lang J, Nunez-Avellaneda D, Behbakht K, Davidson NR, Woodruff ER, Villagomez FR.   +6 more
europepmc   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source